Hydroxychloroquine in COVID-19 widespread use despite unproven benefit
Saved in:
| Main Author: | Pranav Ish |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-01-01
|
| Series: | Indian Journal of Rheumatology |
| Online Access: | http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2022;volume=17;issue=2;spage=213;epage=213;aulast= |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Risk versus Benefit of Using Hydroxychloroquine to Treat Patients with COVID-19
by: George G. Zhanel, et al.
Published: (2021-01-01) -
Analysis of hydroxychloroquine prescriptions for COVID‐19 in Japan
by: Takashi Watari, et al.
Published: (2023-05-01) -
The pharmaceutical suitcase trade and the need for multisectoral regulation-unproven COVID-19 (Ivermectin and HCQ remedies unmask an insidious health danger in a Caribbean Island)
by: Sandeep Bhupendra Maharaj, et al.
Published: (2024-12-01) -
Usefulness of hydroxychloroquine for COVID-19: Does answer lie in timing to start?
by: Mohan Gurjar, et al.
Published: (2020-01-01) -
Hydroxychloroquine Effects on TLR Signalling: Underexposed but Unneglectable in COVID-19
by: Aliede E. in ‘t Veld, et al.
Published: (2021-01-01)